TY - JOUR
T1 - Immunomodulation of invasive fungal infections
AU - Roilides, Emmanuel
AU - Lyman, Caron A.
AU - Panagopoulou, Paraskevi
AU - Chanock, Stephen
N1 - Funding Information:
Paraskevi Panagopoulou was supported by the Grant PENED99 ED14 from the Hellenic Ministry of Development.
PY - 2003/3/1
Y1 - 2003/3/1
N2 - Genetic and acquired (disease- or therapy-related) host immune factors increase the risk for IFIs. In addition to antifungal drug therapy, modulation of host defenses by the use of HGFs and IFN-γ has been supported by extensive in vitro and in vivo preclinical data. Clinical studies on the prevention or the adjunctive therapy of IFIs in combination with antifungal agents are limited, however, and do not allow specific recommendations for their cost-effective use in most of the immunodeficient settings. There is an urgent need to push forward with well-structured, randomized clinical trials to determine optimal dose, duration, and timing for different combinations of immunotherapy and antifungal agents in high-risk patients.
AB - Genetic and acquired (disease- or therapy-related) host immune factors increase the risk for IFIs. In addition to antifungal drug therapy, modulation of host defenses by the use of HGFs and IFN-γ has been supported by extensive in vitro and in vivo preclinical data. Clinical studies on the prevention or the adjunctive therapy of IFIs in combination with antifungal agents are limited, however, and do not allow specific recommendations for their cost-effective use in most of the immunodeficient settings. There is an urgent need to push forward with well-structured, randomized clinical trials to determine optimal dose, duration, and timing for different combinations of immunotherapy and antifungal agents in high-risk patients.
UR - http://www.scopus.com/inward/record.url?scp=0344837394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344837394&partnerID=8YFLogxK
U2 - 10.1016/S0891-5520(02)00070-3
DO - 10.1016/S0891-5520(02)00070-3
M3 - Review article
C2 - 12751266
AN - SCOPUS:0344837394
VL - 17
SP - 193
EP - 219
JO - Infectious Disease Clinics of North America
JF - Infectious Disease Clinics of North America
SN - 0891-5520
IS - 1
ER -